{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:37:26Z","timestamp":1760236646825,"version":"build-2065373602"},"reference-count":36,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T00:00:00Z","timestamp":1639008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and objectives: The diagnosis and therapy of squamous cell carcinoma of the anus may vary significantly in daily clinical practice, even if international guidelines are available. Materials and Methods: We conducted a pattern of care survey to assess the management of patients with anal cancer in Italy (38 questions). We analyzed 58 questionnaires. Results: Most of the respondents work in public and\/or university hospitals (75.8%) in northern Italy (65.5%). The majority (88.0%) treat less than 20 patients\/year. Common examinations for diagnosis and staging are anorectal endoscopy (84.5%), computed tomography scan (86.2%) and pelvic magnetic resonance imaging (MRI) (96.5%). The most frequently prescribed dose to primary tumor is 50\u201354 Gy (46.5\u201358.6%) for early stage disease and 54\u201359.4 Gy (62.1\u201332.8%) for locally advanced cases. Elective volumes are prescribed around 45 Gy (94.8%). Most participants use volumetric intensity modulated radiotherapy (89.7%) and a simultaneous integrated boost (84.5%). Concurrent radiotherapy, 5-fluorouracil and mitomycin is considered the standard of care (70.6%). Capecitabine is less frequently used (34.4%). Induction chemotherapy is an option for extensive localized disease (65.5%). Consolidation chemotherapy is rarely used (18.9%). A response evaluation is conducted at 26\u201330 weeks (63.9%) with a pelvic MRI (91.4%). Follow-up is generally run by the multidisciplinary tumor board (62.1%). Conclusions: Differences were observed for radiotherapy dose prescription, calling for a consensus to harmonize treatment strategies.<\/jats:p>","DOI":"10.3390\/medicina57121342","type":"journal-article","created":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T21:46:58Z","timestamp":1639086418000},"page":"1342","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Pattern of Care Report on the Management of Patients with Squamous Cell Carcinoma of the Anus\u2014A Study by the Italian Association of Radiotherapy and Clinical Oncology (AIRO) Gastrointestinal Tumors Study Group"],"prefix":"10.3390","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2276-0687","authenticated-orcid":false,"given":"Pierfrancesco","family":"Franco","sequence":"first","affiliation":[{"name":"Department of Translational Medicine, University of Eastern Piedmont, Via Solaroli 17, 28100 Novara, Italy"},{"name":"Department of Radiation Oncology, \u2018Maggiore della Carita\u2019 University Hospital, Via Solaroli 17, 28100 Novara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7722-290X","authenticated-orcid":false,"given":"Giuditta","family":"Chiloiro","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario \u2018Agostino Gemelli\u2019 IRCCS, Via della Pineta Sacchetti, 00168 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giampaolo","family":"Montesi","sequence":"additional","affiliation":[{"name":"Radiation Oncology Department, \u2018S.M. Della Misericordia\u2019 Hospital, AULSS 5 Veneto, Viale Tre Martiri 140, 45100 Rovigo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Montrone","sequence":"additional","affiliation":[{"name":"Radiation Oncology Unit, Pisa University Hospital, Via Roma 67, 56123 Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0253-8958","authenticated-orcid":false,"given":"Alessandra","family":"Arcelli","sequence":"additional","affiliation":[{"name":"Radiation Oncology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Massarenti 9, 40138 Bologna, Italy"},{"name":"Department of Experimental, Diagnostic and Specialty Medicine-DIMES, Alma Mater Studiorum, Bologna University, Via Massarenti 9, 40138 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiziana","family":"Comito","sequence":"additional","affiliation":[{"name":"Radiotherapy Department, Humanitas Clinical and Research Hospital IRCCS, Via Manzoni 56, Rozzano, 20089 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Arcadipane","sequence":"additional","affiliation":[{"name":"Department of Oncology, Radiation Oncology, AOU \u2018Citta\u2019 della Salute e della Scienza\u2019, Via Cavour 31, 10123 Turin, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1308-0113","authenticated-orcid":false,"given":"Luciana","family":"Caravatta","sequence":"additional","affiliation":[{"name":"Radiation Oncology Unit, \u2018SS Annunziata Hospital\u2019, \u2018G. D\u2019Annunzio\u2019 University of Chieti-Pescara, Via dei Vestini, 66100 Chieti, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0529-201X","authenticated-orcid":false,"given":"Gabriella","family":"Macchia","sequence":"additional","affiliation":[{"name":"Radiation Oncology Unit, Gemelli Molise Hospital\u2013Universita\u2019 Cattolica del Sacro Cuore, Largo Agostino Gemelli 1, 86100 Campobasso, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Lupattelli","sequence":"additional","affiliation":[{"name":"Radiation Oncology Section, Perugia General Hospital, Piazzale Meneghini 1, 06156 Perugia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina Rita","family":"Niespolo","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Azienda Ospedaliera S. Gerardo, Via Pergolesi 33, 20900 Monza, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0255-8986","authenticated-orcid":false,"given":"Fernando","family":"Munoz","sequence":"additional","affiliation":[{"name":"Radiation Oncology Department, \u2018Umberto Parini\u2019 Regional Hospital, AUSL Valle d\u2019Aosta, Aosta, Viale Ginevra 3, 11100 Aosta, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Palazzari","sequence":"additional","affiliation":[{"name":"Radiation Oncology Department, Oncological Referral Center, Via Gallini 2, 33081 Aviano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2064-8379","authenticated-orcid":false,"given":"Marco","family":"Krengli","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, University of Eastern Piedmont, Via Solaroli 17, 28100 Novara, Italy"},{"name":"Department of Radiation Oncology, \u2018Maggiore della Carita\u2019 University Hospital, Via Solaroli 17, 28100 Novara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Valvo","sequence":"additional","affiliation":[{"name":"Scientific Direction Unit, National Center for Oncological Hadrontherapy (CNAO), Strada Campeggi 53, 27100 Pavia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Antonietta","family":"Gambacorta","sequence":"additional","affiliation":[{"name":"Fondazione Policlinico Universitario \u2018Agostino Gemelli\u2019 IRCCS, Via della Pineta Sacchetti, 00168 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Genovesi","sequence":"additional","affiliation":[{"name":"Radiation Oncology Unit, \u2018SS Annunziata Hospital\u2019, \u2018G. D\u2019Annunzio\u2019 University of Chieti-Pescara, Via dei Vestini, 66100 Chieti, Italy"},{"name":"Department of Neuroscience, Imaging and Clinical Sciences, \u2018G.D\u2019Annunzio\u2019, University of Chieti-Pescara, Via dei Vestini 31, 66100 Chieti, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Mantello","sequence":"additional","affiliation":[{"name":"Department of Oncology and Radiotherapy, Azienda Ospedaliero Universitaria Ospedali Riuniti, Via Conca 71, Torrette, 60002 Ancona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): A randomised, phase 3, open-label, 2 \u00d7 2 factorial trial","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1001\/jama.299.16.1914","article-title":"Fluorouracil, mitomycin, and radiotherapy vs. fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: A randomized controlled trial","volume":"299","author":"Ajani","year":"2008","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3109\/07357907.2015.1028586","article-title":"Intensity-modulated radiation therapy with simultaneous integrated boost combined with concurrent chemotherapy for the treatment of anal cancer patients: 4-year results of a consecutive case series","volume":"33","author":"Franco","year":"2015","journal-title":"Cancer Investig."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1200\/JCO.19.03266","article-title":"International rare cancers initiative multicenter randomized phase II trial of cisplatin and fluorouracil versus carboplatin and paclitaxel in advanced anal cancer: InterAAct","volume":"38","author":"Rao","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(18)30321-8","article-title":"Docetaxel, cisplatin and fluorouracil chemotherapy for metastastic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): A multicenter, single-arm, phase 2 study","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2015832","DOI":"10.1259\/bjr.20150832","article-title":"Volumetric modulated arc therapy (VMAT) in the combined modality treatment of anal cancer patients","volume":"89","author":"Franco","year":"2016","journal-title":"Br. J. Radiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/ajco.12768","article-title":"Image-guided IMRT with simultaneous integrated boost as per RTOG 0529 for the treatment of anal cancer","volume":"14","author":"Arcadipane","year":"2018","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.annonc.2021.06.015","article-title":"Anal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow up","volume":"32","author":"Rao","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.radonc.2014.04.013","article-title":"Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"111","author":"Nilsson","year":"2014","journal-title":"Radiother Oncol."},{"key":"ref_10","unstructured":"(2019, September 26). Anal IMRT Guidance. Available online: http:\/\/analimrtguidance.co.uk\/."},{"key":"ref_11","unstructured":"(2019, September 26). NCCN Guideline Anal Cancer. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/anal.pdf."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.ijrobp.2011.12.058","article-title":"Australasian gastrointestinal trials group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer","volume":"83","author":"Ng","year":"2012","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_13","unstructured":"Associazione Italiana Radioterapia Oncologica (2021, July 27). Gruppo di Studio per i Tumori Gastrointestinali. La Radioterapia dei Tumori Gastrointestinali. Indicazioni e Criteri Guida. Edizione Tascabile. Available online: www.radioterapiaitalia.it\/linee-guida-raccomadazioni\/linee-guida-della-disciplina."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Caravatta, L., Mantello, G., Valvo, F., Franco, P., Gasparini, L., Rosa, C., Slim, N., Manfrida, S., De Felice, F., and Gerardi, M.A. (2021). Radiotherapy with intensity-modulated (IMRT) techniques in the treatment of anal carcinoma (RAINSTORM): A multicenter study on behalf of AIRO (Italian Association of Radiotherapy and Clinical Oncology) Gastrointestinal Study Group. Cancers, 13.","DOI":"10.3390\/cancers13081902"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.2196\/jmir.6.3.e34","article-title":"Improving the quality of web surveys: The checklist for reporting results of internet E-surveys (CHERRIES)","volume":"6","author":"Eysenbach","year":"2004","journal-title":"J. Med. Internet Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13014-020-01539-x","article-title":"Management of anal cancer patients\u2014A pattern of care analysis in German-speaking countries","volume":"15","author":"Martin","year":"2020","journal-title":"Radiat. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00066-021-01842-w","article-title":"Practice of radiation therapy for anal cancer in Austria\u2014A survey on behalf of the Austrian radiation oncology society gastrointestinal tumor group (\u00d6GRO-GIT)","volume":"197","author":"Gerum","year":"2021","journal-title":"Strahelenther Onkol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1245\/s10434-015-4391-9","article-title":"The role of FDG-PET in the initial staging and response assessment of anal cancer: A systematic review and meta-analysis","volume":"22","author":"Jones","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Arcadipane, F., Silvetti, P., Olivero, F., Gastino, A., De Luca, V., Mistrangelo, M., Cassoni, P., Racca, P., Gallio, E., and Lesca, A. (2020). Bone marrow-sparing IMRT in anal cancer patiejts undergoing concurrent chemo-radiation: Results of the first phase of a prospective phase II trial. Cancers, 12.","DOI":"10.3390\/cancers12113306"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Arcadipane, F., Solvetti, P., Olivero, F., Gastino, A., Carlevato, R., Chiovatero, I., Spinelli, L., Mistrangelo, M., Cassoni, P., and Ritorto, G. (2021). Concurrent chemoradiation in anal cancer patients delivered with bone marrow-sparing IMRT: Final results of a prospective phase II trial. J. Pers. Med., 11.","DOI":"10.3390\/jpm11050427"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.clon.2016.12.010","article-title":"Are there HIV-specific differences for anal cancer patients treated with standard chemoradiation in the era of combined antiretroviral therapy?","volume":"29","author":"Martin","year":"2017","journal-title":"Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"8081","DOI":"10.18632\/oncotarget.23545","article-title":"The prognostic value of HPV combined p16 status in patients with anal squamous cell carcinoma: A meta-analysis","volume":"9","author":"Sun","year":"2018","journal-title":"Oncotarget"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijrobp.2012.09.023","article-title":"RTOG 0529: A phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mytomicin-C for the reduction of acute morbidity in carcinoma of the anal canal","volume":"86","author":"Kachnic","year":"2013","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.adro.2017.01.009","article-title":"Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529","volume":"2","author":"Mitra","year":"2017","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s13014-018-1124-9","article-title":"Comparing simultaneous integrated boost vs sequential boost in anal cancer patients: Results of a retrospective observational study","volume":"13","author":"Franco","year":"2018","journal-title":"Radiat. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.radonc.2014.10.002","article-title":"Anal carcinoma\u2014Survival and recurrence in a large cohort of patients treated according to Nordic guidelines","volume":"113","author":"Leon","year":"2014","journal-title":"Radiother. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2011.35.4837","article-title":"Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: Final analysis of the randomized UNICANCER ACCORD 03 trial","volume":"30","author":"Peiffert","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.radonc.2018.08.008","article-title":"Prognostic factors of colostomy free survival in patients presenting with locally advanced anal canal carcinoma: A pooled analysis of two prospective trials (KANAL 2 and ACCORD 03)","volume":"129","author":"Faivre","year":"2018","journal-title":"Radiother. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"E164","DOI":"10.1016\/j.ijrobp.2016.06.1006","article-title":"The development of an umbrella trial (PLATO) to address radiation therapy dose questions in the locoregional management of squamous cell carcinoma of the anus","volume":"96","author":"Adams","year":"2016","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ijrobp.2019.10.016","article-title":"Patterns and predictors of relapse following radiacal chemoradiation therapy delivered using intensity modulated radiation therapy with simultanoues integrated boost in anal squamous cell carcinomas","volume":"106","author":"Shakir","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.radonc.2015.08.015","article-title":"Chemoradiotherapy for squamous cell carcinoma of the anal canal: Comparison of one versus two cycles of mytomicin-C","volume":"117","author":"White","year":"2015","journal-title":"Radiother. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s12094-016-1504-2","article-title":"Dosimetric predictors of acute hematologic toxicity during concurrent intensity-modulated radiotherapy and chemotherapy for anal cancer","volume":"19","author":"Franco","year":"2017","journal-title":"Clin. Transl. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.ijrobp.2018.04.033","article-title":"Toxicity, tolerability, and complicance of concurrent capecitabine or 5-fluorouracil in radical management of anal cancer with single-dose mitomycin-C and intensity modulated radiation therapy: Evaluation of a national cohort","volume":"101","author":"Jones","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ijrobp.2018.04.076","article-title":"Extended-field chemoradiation therapy for definitive treatment of anal canal squamous cell Carcinoma involving the para-aortic lymph nodes","volume":"102","author":"Holliday","year":"2018","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(17)30071-2","article-title":"Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): A post-hoc analysis of randomised controlled phase 3 trial","volume":"18","author":"Meadows","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Guren, M.G., Sebag-Montefiore, D., Franco, P., Johnsson, A., Segelov, E., Deutsch, E., Rao, S., Spindler, K.L., and Arnold, D. (2021). Treatment of squamous cell carcinoma of the anus, unresolved areas and future perspective for research. Perspective of research needs in anal cancer. Clin. Colorect. Cancer, in press.","DOI":"10.1016\/j.clcc.2021.09.006"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/12\/1342\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:43:57Z","timestamp":1760168637000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/12\/1342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,9]]},"references-count":36,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["medicina57121342"],"URL":"https:\/\/doi.org\/10.3390\/medicina57121342","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2021,12,9]]}}}